SCHEMBL1010645

SCHEMBL1010645

CC(=O)c1ccccc1Oc1cn[nH]c(=O)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.40
ALDH1A1 P00352 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
KDM4E B2RXH2 1/20 0.40
SCN8A Q9UQD0 2/20 0.39
SCN10A Q9Y5Y9 2/20 0.39
CTNNB1 P35222 1/20 0.39
MAPT P10636 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
DDB1 Q16531 1/20 0.38
CRBN Q96SW2 1/20 0.38
MAPK1 P28482 1/20 0.38
HSD17B10 Q99714 1/20 0.38
PTGS1 P23219 1/20 0.37
ADRA2A P08913 1/20 0.37
ADRA2B P18089 1/20 0.37
ADRA2C P18825 1/20 0.37
KMT2A Q03164 3/20 0.37
MIF P14174 1/20 0.37
MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1008229 0.86 CTNNB1 (0.56) LMNAALDH1A1SMN1; SMN2KDM4ESCN8A
SCHEMBL1008641 0.77 PRMT5 (0.43) ALDH1A1PTGS1KMT2A
SCHEMBL24449871 0.76 ALDH1A1 (0.59) ALDH1A1SCN8ASCN10AMAPK1HSD17B10
SCHEMBL9638920 0.75 CTNNB1 (0.58) LMNAALDH1A1SMN1; SMN2KDM4ECTNNB1
SCHEMBL1008211 0.74 SMN1; SMN2 (0.40) LMNAALDH1A1SMN1; SMN2KDM4EMAPT
SCHEMBL1009006 0.74 LTA4H (0.44) PTGS1TSHRALOX15ALOX12
SCHEMBL3179214 0.73 CTNNB1 (0.67) LMNAALDH1A1SMN1; SMN2KDM4ECTNNB1
SCHEMBL29679671 0.73 CTNNB1 (0.67) LMNAALDH1A1SMN1; SMN2KDM4ECTNNB1
SCHEMBL1009652 0.73 TRPA1 (0.40) SCN8ASCN10A
SCHEMBL5708950 0.73 LMNA (0.60) LMNAALDH1A1SMN1; SMN2KDM4ECTNNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 US disclosed
EP-2268633-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2011-01-05 EP disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
WO-2009127544-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS GCK, GCKR, PDXK LMNA 3588/4885ALDH1A1 1059/4885SMN1; SMN2 2837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.